Parasite‐Derived IL‐33 Inhibitors Prevent Bleomycin‐Induced Lung Fibrosis
European Journal of Immunology · 2026-10 · 56 (10)
DOI: 10.1002/eji.70291 ↗Abstract
ABSTRACT Idiopathic pulmonary fibrosis (IPF) is a progressive lung‐scarring disease in which epithelial injury, consequent release of alarmins such as interleukin (IL)‐33, and immune activation contribute to extracellular matrix deposition. The intestinal helminth Heligmosomoides polygyrus bakeri ( Hpb ) secretes immunomodulators that suppress type 2 immunity, including HpARI2, which binds IL‐33, and HpBARI_Hom2, which blocks the IL‐33 receptor ST2. Here, we test this parasite‐derived dual blockade strategy in the bleomycin (BLM) mouse model, moving from live Hpb infection to administration of total Hpb excretory/secretory products (HES), and finally administering recombinant HpARI2 and HpBARI_Hom2 proteins. Hpb infection and HES treatment prevented BLM‐induced lung fibrosis when administered during the early inflammatory phase. Recombinant HpARI2+HpBARI_Hom2 reproduced this protection, reduced collagen deposition and hydroxyproline accumulation, and dampened ILC2, eosinophil, macrophage, and neutrophil responses. In contrast, HES or HpARI2+HpBARI_Hom2 administration failed to reverse established fibrosis when administered later in the model. Similarly, administration of the IL‐33trap fusion protein could replicate these effects, suppressing fibrosis when administered in the early inflammatory, but not later fibrotic phases of this model. These findings identify parasite‐derived inhibition of the IL‐33 axis as a defined molecular mechanism by which helminth products can prevent early inflammatory fibrogenesis, while also demonstrating that IL‐33 blockade is unlikely to reverse established lung scarring.
EUVIMED